High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) is sponsored by U.S. Department of Health & Human Services: National Institutes of Health (NIH). This funding opportunity supports innovative research addressing the intersection of HIV and substance use, including new avenues for prevention, treatment, and potential cures for HIV among people who use drugs.

RFA-DA-25-060: High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Institute on Drug Abuse ( NIDA ) Funding Opportunity Title High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) RM1 Research Project with Complex Structure Notices of Special Interest associated with this funding opportunity January 28, 2026 - NIH Removing AIDS Application Due Dates from NOFOs.

See Notice NOT-OD-26-029 . March 31, 2025 - This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.

April 04, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084 March 20, 024 - Notice of Pre-Application Technical Assistance Webinar for RFA-DA-25-060. See Notice NOT-DA-24-019 .

August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198 . August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy.

See Notice NOT-OD-22-189 . Funding Opportunity Number (FON) Companion Funding Opportunity See Section III. 3.

Additional Information on Eligibility . Assistance Listing Number(s) Funding Opportunity Purpose The purpose of this notice of funding opportunity (NOFO) is to support high priority research at the intersection of HIV and substance use.

This NOFO invites research projects with the potential to open new areas of basic and clinical HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. This initiative is open only to research teams of three to six PD/PIs proposing to pursue challenging research questions at the intersection of HIV and substance use.

Teams are encouraged to consider far-reaching objectives that will produce major advances in high priority HIV research areas for the institute and the NIH ( NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding ).

This NOFO addresses basic science, epidemiologic, clinical, intervention, and implementation research related to HIV in people with substance use and substance use disorders (SUDs).

Open Date (Earliest Submission Date) Letter of Intent Due Date(s) 30 days prior to the application due date Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. New Date March 6, 2027 per issuance of NOT-OD-26-029 .

(Original Expiration Date: January 08, 2027) Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants. gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

Use the NIH ASSIST system to prepare, submit and track your application online. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants. gov and eRA Commons to track your application.

Check with your institutional officials regarding availability. Workspace to prepare and submit your application and eRA Commons to track your application. Part 1.

Overview Information Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II.

Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V.

Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII.

Other Information Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description The purpose of this notice of funding opportunity (NOFO) is to support high priority research at the intersection of HIV and substance use.

This NOFO invites research projects with the potential to open new areas of basic and clinical HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. The scope of this NOFO includes basic science, epidemiologic, clinical, intervention, and implementation research.

This initiative is open only to research teams of three to six PD/PIs proposing to pursue challenging research questions at the intersection of HIV and substance use. Teams are encouraged to consider far-reaching objectives that will produce major advances in high priority HIV research areas for the institute and the NIH ( NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding ).

The proposed program goal must only be achievable by an interdisciplinary, collaborative research plan that creatively combines a variety of expertise, approaches and/or research methodologies. Applications submitted under this NOFO are required to have a detailed research plan, preliminary data, and a clear description of the nexus between HIV and substance use.

This NOFO is not intended for applications proposing projects that only expand existing research programs, nor for applications that focus only on development of new technologies, medications and/or infrastructure.

Additionally, the RM1 program is distinct from the National Institute on Drug Abuse ( NIDA) P01 , NIDA P50 , and NIH parent R01 initiatives because it will support a single-focused, ambitious, and challenging project that cannot be addressed by individual R01 applications.

Substance use remains a key driver of new HIV infections and an important factor affecting clinical and health outcomes related to HIV and HIV-associated comorbidities. People who use substances often experience gaps in the HIV care continuum.

New HIV cases in the US disproportionately occur among young adults, while persons living with HIV have increasingly longer lives which necessitate a lifespan perspective and recognition that patterns of substance use can vary across the life course. People living chronically with HIV and substance use also face the risk of multiple cardiovascular, respiratory, neurological and psychiatric comorbidities that affect health outcomes.

This NOFO is therefore designed to attract exceptionally talented teams of investigators to conduct cutting-edge research at the intersection of HIV and substance use to stimulate basic HIV/substance use research and inform effective HIV prevention, care and cure strategies.

Listed below are the NIDA’s HIV research priorities: Prevent new infections and transmission of HIV among people with substance use and substance use disorders (SUDs) and their sexual and/or injection partners. Increase the understanding of HIV etiology, pathogenesis, spread, and persistence among people with substance use and SUDs. Address comorbidities and improve health outcomes among people with HIV and use addictive substances.

Accelerate scientific discoveries at the intersection of HIV/AIDS and substance use research. Program Objectives and Scope Applications responding to this NOFO are required to have a single overarching goal and an integrated research plan that incorporates multiple perspectives and disciplines to deliver transformative outcome(s) within the 5-year award period.

This NOFO will support interdisciplinary teams that seek to cross methodologic and conceptual boundaries through interdisciplinary collaboration to achieve a single, focused, and transformative goal. The research goal must be well-defined and sufficiently focused so that meaningful outcomes can be accomplished within 5 years.

It should also be of sufficient scope and complexity that it can only be achieved through an integrative interdisciplinary team effort and not by individual, parallel, or series of efforts. All contributions by each team member and components of the research plan are expected to come together in ways that are synergistic, integrated, and essential to the overarching goal.

Applications submitted under this NOFO are required to have a detailed research plan, preliminary data, and a clear description of the intersection between HIV and substance use that will be addressed. The proposed program goal must only be achievable by an interdisciplinary, collaborative research plan that creatively combines a variety of expertise, approaches and/or research methodologies.

The major thrust of the project must align with NIDA and NIH HIV research priorities described above. Addictive substances that are of interest include opioids, nicotine, cocaine, methamphetamine, other stimulants, prescription drugs, cannabinoids, xylene, or combinations of drugs (including alcohol).

The list below includes representative, but not exhaustive, examples of interdisciplinary opportunities applicable to high priority research at the intersection of HIV and substance use : Challenges existing paradigms of HIV testing, prevention an/or care, and overcomes long-standing roadblocks to progress in these areas.

Develops new strategies based on systems-science approaches to drive innovative, transformative approaches of HIV testing, prevention, and/or care. Basic, translational, and/or clinical collaborations with a goal of reaching a significantly higher mechanistic understanding HIV and HIV latency in the central nervous system (CNS) including neurocognitive impairment in the context of HIV and substance use.

Overcomes challenges in providing optimized ‘whole-person’ care (treatment for HIV, SUD, and comorbidities, and support services) that requires collaborations across various disciplines including clinical sciences, social and behavioral sciences, health economics, computational statistics, epidemiology, and implementation science etc. Address social determinants of health as they relate to the intersection of HIV and substance use in ways that go beyond descriptive research or interventions that focus on individual-level consequences of social/structural factors affecting health.

Scientific efforts requiring integration of previously siloed and/or disparate areas of scientific, clinical or technical expertise relevant to HIV and substance use research fields. Challenges that necessitate bridging across species, systems (3D-tissue models), scales and disciplines to reveal shared/generalizable and/or unique biological processes linked to pathogenesis and persistence of HIV and the HIV-related comorbidities.

Particularly in the case of clinical and/or implementation science applications, multidisciplinary teams are encouraged to partner with the potential end-users of the knowledge/data that would be generated (e.g., AIDS service organizations, public health officials, health departments, justice systems, policymakers, community organizations, clinical providers, etc.).

These partnerships should be documented and can include new or existing relationships. The application should describe these relationships and indicate how knowledge would be used to inform decision-making and practices in their settings. Non-Responsiveness Criteria: Applications deemed to be non-responsive will not proceed to review and will be withdrawn.

The following are considered non-responsive to this NOFO: Applications including research that does not align with NIDA and NIH HIV research priorities described above. Applications focused solely on alcohol exposure. Applications proposing only to discover and/or develop a small molecule, biologic therapeutic, or therapeutic device to treat SUD or HIV and HIV-associated comorbidities.

Clinical trials designed to answer only specific questions related to safety, tolerability, acceptability, or efficacy of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions (e.g., phase I, phase II, phase III, or pivotal clinical trials).

PIs are strongly encouraged to discuss any planned clinical trial in consideration for this opportunity with the scientific program contact to avoid errors in interpretation. Applications proposing research and data collection outside the US will not be accepted. Applications that include foreign components are permitted where they support domestic research projects to be conducted in the US.

This NOFO calls for highly transformative, innovative and bold programs with a single well-defined overarching objective instead of multiple specific aims and/or projects. This program also requires a Multiple PD/PI (MPI) structure with three to six PD/PIs who will each bring a distinct scientific viewpoint or expertise necessary to pursue the transformative goal.

Each PI is expected to provide a significant, indispensable, and distinct contribution to the project. Teams must not be dominated by a single individual.

Applications for smaller projects with one or two PD/PIs should consider submitting a multi-PD/PI application to the "NIH Research Project Grant (Parent R01)" or the companion funding opportunity for this NOFO i.e. RFA-DA-22-040 When applicable, applications proposing studies with human subject samples are strongly encouraged to use NIDA funded and co-funded data and specimen resources openly available for investigators engaged in research on HIV and SUDs.

Examples include: PhenX Toolkit ( https://www. phenxtoolkit. org/ ), NIDA Longitudinal Cohort studies of people with HIV and SUD, MACS/WIHS Combined Cohort Study (MWCCS) ( https://statepi.

jhsph. edu/mwccs/ ), International epidemiology Databases to Evaluate AIDS, (IeDEA) ( https://www. iedea.

org/ ), The National NeuroAIDS Tissue Consortium (NNTC) ( https://nntc. org/ ), The CNS HIV Antiretroviral Therapy Effects Research Study (CHARTER) ( https://nntc. org/charter-study-0 ) and Veterans Aging Cohort Study (VACS) ( https://medicine.

yale. edu/intmed/vacs/ ). The success of team science hinges on well-managed team interactions, clear timelines and benchmarks for success.

Therefore, the following four components are required as "Other Project Information" as an attachment (see Section IV for instructions). Applications that fail to include these attachments will be considered incomplete and will be withdrawn.

Information in the “Multiple PD/PI Leadership Plan” leadership plan is complementary to the Team Management plan; whereas the “Multiple PD/PI Leadership Plan” describes leadership by and interactions across the PD/PIs, the “Team Management Plan” focuses on management of the whole team/key personnel. Studies of team science have highlighted the need for effective management to achieve program goals, especially as the team size increases.

Many resources exist to aid in developing effective team-based programs (see e.g., the NCI Collaboration and Team Science Field Guide ).

The team management plan will address the following points (see section IV): Organizational structure, team composition, and roles Procedures and structures for resolving conflict among the research team Shared vision, contributions, and distributed responsibility for decision-making Resource sharing and allocation Coordination and communication Intra-team data sharing, archiving, and preservation Because teams will likely include individuals from widely divergent scientific backgrounds, teams are expected to have a shared vision and a defined plan for communication and management of shared responsibilities, interpersonal interactions, and professional credit.

Teams are expected to have at a minimum adequate HIV and substance use expertise together with other needed skill categories to accomplish the overall goal of the program. It is highly recommended that a scientific project manager or program coordinator is included in the team.

Depending on the specific data needs of the project, resource sharing and management systems and/or hiring of professional data science staff should also be considered. 2. Timeline and Benchmarks for Success The research goal for this team science effort is expected to be feasible, well-defined, and sufficiently focused so that transformative outcomes can be achieved within 5 years.

Teams are expected to be intentional about integrating efforts; the extent of integration will be reflected in the presence and types of activities, planned outcomes, and/or framework that will combine and integrate efforts across disciplines and team members. Benchmarking is a data-driven process that helps you create standards to measure the team's success.

Setting benchmarks (milestones) is a simple way to set clear expectations for the team. A diagram explaining the overall structure of the research program and how the various teams/components fit within the overall goal for the program 4.

Infrastructure, partnerships and collaborations As applicable to the program, applications are to include a table listing resources (tool kits, data platforms, training or other such relevant resources) and Partnerships and/or collaborations (e.g. AIDS-service organizations, community-based organizations, health departments, substance use agencies, health care funding organizations).

Projects that incorporate multiple streams related to HIV and substance use services (e.g., those supported by CDC, HRSA, and/or SAMHSA) are encouraged for studies focusing on transformation of service delivery. Important points to consider before applying: Consultation with NIDA program staff As part of NIH, NIDA strives for rigor and transparency in all research it funds.

For this reason, NIDA explicitly emphasizes the NIH application instructions related to rigor and transparency . For example, the biological rationale for the proposed experiments must be based on rigorous and robust supporting data, which means that data should be collected via methods that minimize the risk of bias and be reported in a transparent manner.

If previously published or preliminary studies do not meet these standards, applicants should address how the current study design addresses the deficiencies in rigor and transparency. Proposed experiments should likewise be designed in a manner that minimizes the risk of bias and ensures validity of experimental results. See Section VIII.

Other Information for award authorities and regulations. Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs. Section II.

Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. Application Types Allowed The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Optional: Accepting applications that either propose or do not propose clinical trial(s). Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards NIDA intends to commit $3.

0 M in FY 2025, 2026, and 2027 to fund one-two awards. Individual award budgets are not to exceed $1. 5M per Fiscal Year in direct costs and should reflect the actual scope of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information All organizations administering an eligible parent award may apply for a supplement under this NOFO.

Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are allowed. Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award.

All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications for additional information.

System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.

NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process.

The same UEI must be used for all registrations, as well as on the grant application. eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registration; all registrations must be in place by time of submission.

eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application. Grants. gov – Applicants must have an active SAM registration in order to complete the Grants.

gov registration. Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.

If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide. This NOFO requires a multiple PD/PI application, with 3-6 PDs/PIs.

Each of the Principal Investigators in the team of 3-6 investigators is required to have equivalent effort because the NOFO expects each PI to provide a significant, indispensable, and distinct contribution to the project. Teams should not be dominated by a single individual. Multiple PDs/PIs on a project share the authority and responsibility for leading and directing the project, intellectually and logistically.

Generally, each PD/PI should devote at least 2. 4 person months (i.e., the equivalent of 20% effort on a full-year appointment, 26. 7% on a 9-month appointment, or 40% on a 6-month appointment) throughout the duration of the award.

Multiple PD/PI leadership plan is required as a special attachment. Visit the multiple PD/PI Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide, and the Grant Policy Statement on Multiple Principal Investigators. Minimum allowed efforts by the PDs/PIs are described in the R&R Budget instructions in Part 2.

Section IV. 2. PD(s)/PI(s) who have an active NIDA R35 award can participate as a Collaborator instead of a PD/PI as part of the 50% effort on their current R35 award and may not receive additional funds from this award.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide. This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1. 2 Definition of Terms .

3. Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.

3. 7. 4 Submission of Resubmission Application .

This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3. 9.

4 Similar, Essentially Identical, or Identical Applications ). Section IV. Application and Submission Information 1.

Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.

gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced.

Applications that are out of compliance with these instructions may be delayed or not accepted for review. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review. By the date listed in Part 1.

Overview Information , prospective applicants are asked to submit a letter of intent that includes the following information: Descriptive title of proposed activity Name(s), address(es), and telephone number(s) of the PD(s)/PI(s) Names of other key personnel Participating institution(s) Number and title of this funding opportunity The letter of intent should be sent to: [email protected] All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed.

For this specific NOFO, the Research Strategy section is limited to 15 pages . Instructions for Application Submission The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO. All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations All instructions in the SF424 (R&R) Application Guide must be followed. SF424(R&R) Other Project Information All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions. 1.

Team Management Plan (Required – 3 pages maximum): As an "Other Attachment" entitled “Team Management Plan. pdf”, applicants must address how the entire group will function to accomplish program objectives and vision. Team management approaches raised in the subsections listed below should be described in the Plan.

Note that a "Multiple PD/PI Leadership Plan" is also required as a separate attachment, and the information in that plan should not be duplicated here. Whereas the “Multiple PD/PI Leadership Plan” focuses on leadership by and interactions across the PD/PIs, the “Team Management Plan” focuses on management of the whole team/key personnel.

Applicants are encouraged to consult resources to aid in developing effective team-based programs (see e.g., the NCI Collaboration and Team Science Field Guide and literature on the Science of Team Science) and/or participate in team-science related training. Applications that exceed the 3-page limit will be withdrawn.

Organizational structure, team composition, and roles: The program management structure must avoid giving any single individual undue authority that prevents contributions from the wider team for setting program priorities, resource distribution, and reward.

NIDA recognizes that strong leadership is required for complex team efforts to be successful, while at the same time effective team leadership requires decision-making based on an amalgam of interests, expertise, and roles, guided by recognized project objectives. Of note, teams are expected to have at a minimum adequate HIV and SUD expertise together with other needed skill categories to accomplish the overall goal of the program.

Applicants should develop a management structure based on project objectives that effectively promote the proposed research. The structure should account for team composition, personnel roles, institutional resources, and policies. NIDA does not specify any particular organizational structure, as this may vary across research questions and groups.

Inclusion of a scientific project manager or coordinator as a Senior/Key Person with adequate authority is strongly recommended . If a project manager or coordinator is included, describe how the qualifications of this individual are appropriate for such a role, for the subject matter, and scale of the proposed project.

Shared vision, contributions, and responsibility for decision-making: The Team Management Plan must include a description of how the PD/PIs will establish and sustain an interdisciplinary team of researchers with an optimal range of backgrounds, expertise, and skills to successfully accomplish the goals of the program.

One key consideration is that teams employing complementary approaches and having a broad array of areas of intellectual and technical expertise are more productive if the process for making decisions incorporates different points of view. The Team Management Plan should describe how major decisions will be made or how conflicts will be resolved.

A key characteristic that distinguishes productive teams is the degree that all member contributions are valued. Strategies for building and maintaining group participation to develop collective intelligence are encouraged.

Resource sharing and allocation across the team: Applications must describe management and decision-making processes that promote collective input for allocation of program resources with flexibility when resources may need to be dynamically reallocated to achieve programmatic goals.

A plan for how intra-team, institutional, or regional resources that are integral to the team goals will be shared and made accessible to team members should also be included. Credit assignment: A plan for how credit will be shared, especially with early-career researchers, must be included. Methods for attributing contributions to publications should be described to enable individual professional assessment in joint projects.

Knowledge transfer: Knowledge transfer across disciplines and career stages is critical to innovative team science. Describe activities that will facilitate bridging of knowledge across disparate disciplines. Regarding bridging knowledge across career stages, an important and meaningful impact of team science may come from shaping the next generation of neuroscientists.

Because of the interdisciplinary expertise of the research groups, trainees are exposed to and can learn multiple scientific languages and methodologies, resulting in multi-faceted, early-career researchers. Plans for how trainees will be immersed in, and benefit from, these approaches should be also described.

This could include shared mentorship, inter-lab meetings, all-hands tutorials, shared meeting and document space, inter-lab visits, and trainee presentations. Coordination and Communication plans: Practical aspects must be described, including frequency, logistics, and infrastructure of real time communication across all key personnel, consultants, trainees, and other significant contributors regardless of effort level.

If a scientific project manager or coordinator is included, describe his/her role in coordinating team activities and communication. Intra-team data sharing, archiving, and preservation: A framework for sharing and/or integrating data across team members must